Guilford seeks partners throughout the world for a number of our technologies. The preferred partnering strategy may vary depending on the compound, target indication(s), stage of development and geographic markets. Below is a description of Guilford technologies we are interested in partnering, particularly in the areas indicated.

The information included in the Licensing section of this website is intended solely for initiating partnering discussions with potential development and commercialization collaborators. This information is not intended as prescribing or promotional information and includes forward-looking statements. Physicians or patients looking for prescribing information are referred to our marketed products section. Potential investors are referenced to and reminded that such forward looking statements involve risks and uncertainties, including those described in the section entitled "Risk Factors" from the Company's Quarterly Report on Form 10-Q, filed May 10, 2004, and other filings of the Company with the Securities and Exchange Commission.

Product Stage Target Indication(s)
GPI 5693 and NAALADase program
Phase I Neuropathic pain, cancer and other disorders

GPI 1485 and NIL program Phase II (Guilford and NIH) Parkinson’s disease (PD)

Post-Prostatectomy Erectile Dysfunction
AQUAVAN® Injection Phase III Sedation and anesthesia
PARP inhibitors Research / preclinical (Lead product
selection by 4Q04)
Cancer Sensitization: for both chemotherapy- and radiotherapy

•Central Nervous Systems Disorders: stroke and other ischemic diseases
GLIADEL® Wafer
(polifeprosan 20 with carmustine implant)
Approved and marketed in U.S. and over 20 other countries As an adjunct to surgery and radiation for both
newly diagnosed high grade glioma (HGG)

2nd line glioblastoma multiforme
PACLIMER® Microspheres Phase I

Ovarian cancer

Non-small cell lung cancer
Lidocaine-PE Phase I Controlled release analgesia in post-surgical pain
PhosphoEster biodegradable polymer technology Research Drug delivery, tissue engineering, etc.



This page was last updated on Monday May 24, 2004

Copyright© 2001 Guilford Pharmaceuticals Inc.
Legal Information